TransCode Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, as amended, to January 17, 2023. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence addressed to Mr. Tim Buchmiller at the SEC. The company, represented by interim CEO Thomas Fitzgerald, has indicated its awareness of the responsibilities entailed by the Act. TransCode Therapeutics has also provided contact details for its outside counsel, Goodwin Procter LLP, and has requested oral confirmation of the Registration Statement's effectiveness from the SEC upon approval.

TransCode Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, as amended, to January 17, 2023. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence addressed to Mr. Tim Buchmiller at the SEC. The company, represented by interim CEO Thomas Fitzgerald, has indicated its awareness of the responsibilities entailed by the Act. TransCode Therapeutics has also provided contact details for its outside counsel, Goodwin Procter LLP, and has requested oral confirmation of the Registration Statement's effectiveness from the SEC upon approval.